Hsing-Pang Hsieh

This inventor holds 20 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Kinase Inhibitors. Top assignees: National Health Research Institutes, Anbogen Therapeutics, Inc, Dcb-USA LLC. Active years: 1997-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hsing-Pang Hsieh. Retrieved from https://idiyas.com/inventor/hsing-pang-hsieh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 6)

% Patents Active = 70.0

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 3.4

ph-index = 9

Forward Citations = 234(Granted Patents)

Location History:

Taipei, TW (1997 - 2014)
Zhunan, TW (2014)
Miaoli County, TW (2011 - 2024)

Company Filing History:

17 out of 189

National Health Research Institutes

patents

1 out of 2

Anbogen Therapeutics, Inc

International Chlorella Co., Ltd.

patent

5. 1 out of 1,308

National Tsing Hua University

patents

6. 1 out of 147

Taipei Medical University

patents

7. 1 out of 2,046

The State University of New York

patents

where one patent can have more than one assignee

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

Kinase Inhibitors

Fused Multicyclic Compounds

Protein Kinase

Tyrosine Kinase

Aurora Kinase

Cathepsin S

Viral Infection

Cancer Treatment

Pyrimidine Compounds

Indole Compounds

Pyrrolidine Compounds

Steroidal Polyamines

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12668584 - Heterocyclic compounds as kinase inhibitors for therapeutic uses (2026-06-30),

2. 12240858 - Crystalline forms of (S, E)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2- enamide free base (2025-03-04),

3. 12012400 - Method of the preparation of fused multicyclic compounds (2024-06-18),

4. 9006252 - Fused multicyclic compounds as protein kinase inhibitors (2015-04-14),

5. 8895497 - Cathepsin S inhibitors (2014-11-25),

6. 8710079 - Quinoline compounds and their use for treating viral infection (2014-04-29),

7. 8507502 - Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors (2013-08-13),

8. 8138194 - Fused bicyclic pyrimidine compounds as aurora kinase inhibitors (2012-03-20),

9. 8058427 - Coumarin compounds and their use for treating cancer (2011-11-15),

10. 8048426 - [object Object] (2011-11-01),

11. 7741495 - Indoline-sulfonamides compounds (2010-06-22),

12. 7687504 - Pyrrolidine compounds (2010-03-30),

13. 7632955 - Indole compounds (2009-12-15),

14. 7544712 - Treatment of coronavirus infection (2009-06-09),

15. 7528165 - Indole compounds (2009-05-05),

Title: **Innovative Contributions of Hsing-Pang Hsieh**

Introduction

Hsing-Pang Hsieh is a notable inventor based in Taipei, Taiwan, recognized for his contributions to pharmaceutical science through a series of groundbreaking patents. With a total of 19 patents to his name, Hsieh's work focuses on enhancing drug formulations and stability, pushing the boundaries of contemporary medicine.

Latest Patents

Among Hsieh's recent innovations is a patent describing crystalline forms of (S, E)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide free base, also known as ABT-101. This invention details specific crystalline forms that exhibit unexpected stability and improved pharmacokinetic properties, positioning ABT-101 as a promising candidate for drug development. The pharmaceutical composition and capsule comprising this compound aim to meet bioavailability and drug efficacy standards, representing a significant advancement in therapeutic applications.

Additionally, Hsieh has developed a method for preparing fused multicyclic compounds, which is a manufacturing process designed to produce these compounds on a multikilogram scale effectively. This method enhances efficiency and scalability in pharmaceutical production.

Career Highlights

Hsing-Pang Hsieh has collaborated with esteemed institutions including the National Health Research Institutes and Taipei Medical University. His work in these organizations has significantly contributed to the field of medicine and drug development, ensuring a strong impact on healthcare practices.

Collaborations

Throughout his career, Hsieh has partnered with various researchers, including notable coworkers Yu-Sheng Chao and Jang-Yang Chang. These collaborations have fostered an environment of innovation and have propelled projects that address complex medical challenges.

Conclusion

In conclusion, Hsing-Pang Hsieh's impressive portfolio of patents and collaborations underscores his influence in the pharmaceutical industry. His innovations not only advance drug formulations but also pave the way for improved treatment options, highlighting the essential role inventors play in shaping the future of medicine.

Profile summary based on public USPTO records.